Understanding RA Infusion Drugs Billing for Better Claim Outcomes

Rheumatoid arthritis is an autoimmune, long-term disease that impacts millions of Americans. If oral medications don’t work then physicians may resort to intravenous infusion of biologic drugs. These therapies are clinically effective, but generate massive billing problems for infusion centers. To be reimbursed correctly for RA infusion drugs, it is important to understand and be careful about every detail of the revenue cycle.

From code selection to payer rules to appeals, this article discusses some of the critical areas that impact billing success. You can either bill yourself or use a third-party billing company, but knowing how RA infusion drugs billing works will help you avoid denials and safeguard your revenue.

 

What Are RA Infusion Drugs in Clinical Settings

Infusion drugs for RA are biologic drugs that are injected into the body into a vein and used in people who have moderate to severe RA. They act on specific components of the immune system that cause inflammation and joint damage. Not taken orally, must be administered in a clinical setting under medical supervision.

They are generally used when people are not helped by regular disease-modifying antirheumatic drugs. It takes 30 minutes to a few hours to infuse, depending on the medication being given. Infusions, for example, are frequently provided on a recurring basis with patients needing. To have these claims processed accurately and consistently over the course of time.

 

Common RA Infusion Drugs Used in Rheumatology Practices

There are a number of infusion drugs used in the treatment of RA that can also be administered in an infusion center setting. Each drug has individual billing specifications, dosage, and effects.

• Infliximab (Remicade) is a drug that targets tumor necrosis factor which has been used to treat RA for many years. One of the most commonly billed drugs used for infusion out patients.
• The action of abatacept (Orencia) is to inhibit the activation of T cells and it is given monthly by IV infusion after the loading dose.
• For situations when TNF inhibitors don’t work, rituximab (Rituxan) is used. It is usually administered twice in a period of 14 days.
• Tocilizumab (Actemra) is an anti-IL-6 receptor (IL-6R) agent and has been steadily used over the last decade.

Understanding the drug administered is the first step in accurate RA infusion drugs billing. As each drug will have a different HCPCS code and requirements with the payers.

 

Why RA Infusion Drugs Billing Is Uniquely Complex

In fact, billing for RA infusion treatments is different from billing for routine office visits or straightforward procedures. The complexity is due to having to align multiple layers to pay a claim correctly. Many biologics are dosed based on patient weight and the units to be billed should accurately reflect the patient dosage. The wrong number of units is billed which results in underbilling or denial.

These medications are costly, in addition to being dosed. Payers are very critical of claims for high cost biologics. They want to ensure that the correct diagnosis was noted, that prior authorization was requested and that the medical record demonstrates the medical necessity of the drug. Any missing information is a denial opportunity. That is why it’s important that the infusion drug billing process be well organized from the start.

 

The following is a list of key HCPCS codes that are used for RA infusion drugs billing.

Key HCPCS Codes for RA Infusion Drugs Billing

One of the most frequent billing mistakes in RA infusion drugs billing is using the wrong J code or the wrong number of units. The major codes used are indicated below.

Drug Name	HCPCS Code	Unit Definition
Infliximab (Remicade)	J1745	10 mg per unit
Abatacept (Orencia)	J0129	10 mg per unit
Rituximab (Rituxan)	J9312	100 mg per unit
Tocilizumab (Actemra)	J3262	1 mg per unit
Golimumab (Simponi Aria)	J0717	1 mg per unit

Billers should never submit a claim without first verifying the administered dose with the drug vial size and the definition of the J code unit. Medicaid and some commercial insurance plans will also need the NDC number in addition to the J code.

 

CPT Codes Used With RA Infusion Drugs Claims

As well as the drug’s J code, an administration CPT code is required to bill for the infusion. Each must be included on all claims and substantiated by the clinical documentation.

CPT Code	Description	When to Use
96413	Chemotherapy or therapeutic infusion, first hour	First hour of any RA biologic infusion
96415	Each additional hour beyond the first	When infusion runs longer than 60 minutes
96417	Each additional sequential infusion, different drug	When a second drug is infused after the first one

To bill infusion drugs for RA, you need to use the proper RA J code with the correct RA administration code. Only the drug code or only the administration code will be billed, which will be a partial claim or rejection. Both elements should be consistent with the clinical notes, which should include the duration of infusion and time started/stopped.

 

Prior Authorization Steps for RA Infusion Drugs

Most commercial payers (and many Medicare Advantage plans) require infusion drugs for RA to be covered by prior authorization. One of the most common denial triggers in this specialty is missing or incomplete authorizations. These instructions should be carefully followed for each patient prior to the infusion date.

Step 1: Verify payer requirements before scheduling
Verify with the payer if prior authorization is needed for the drug ordered or with the provider portal. Specific requirements are dependent on the plan and subject to change each year.

Step 2: Gather clinical documentation
Gather patient’s diagnosis information, ICD 10 codes, lab information supporting the RA diagnosis, and a comprehensive physician letter of medical necessity.

Step 3: Document step therapy compliance
Most of the time, payers will need documentation of the patient’s attempts to treat with one or more conventional DMARDs or TNF inhibitors before they will approve a biologic. This documentation should be clear and detailed.

Step 4: Submit the authorization request
Submit the request through the payer portal or by fax with all supporting documentation. Incomplete submissions are the leading cause of authorization delays.

Step 5: Confirm the authorization details
Once approved, make sure to check the authorized drug name, authorized dose, and number of infusions approved, as well as the period for which the authorization is valid. Mismatch authorized drug to billed drug is an automatic denial reason.

Step 6: Attach the authorization number to the claim
Prior authorization number must be submitted with the claim. Clinically accurate, but missing this number will result in an automatic denial.

 

Understanding Drug Wastage Rules in RA Infusion Billing

RA infusion drugs need to be a major billing factor because of drug wastage. Biologic medications are supplied in single use vials and the dose given is not always the full dose in a single vial. That cost is lost to the practice as the leftover medicine can’t be saved or used again.

What the JW Modifier Does

The JW modifier indicates that the remaining drug in a single use vial was properly disposed of after giving the patient the dose. Medicare will pay for this wasted service when the provider bills with the JW modifier attached to the J code. This will enable the practice to receive back the amount that was not used, and insure that the practice does not incur unnecessary losses.

What the JZ Modifier Does

The JZ modifier was added to Medicare to represent no discarded drug from a single use vial as of January 2023. If you used the entire vial and there is no waste, then the JZ modifier should be added to the J code. No claim with this modifier can be accepted by Medicare for coverage under Medicare billing rules as it applies to this modifier.

Payer Specific Wastage Rules

Not every commercial payer abides by Medicare wastage rules. Some will accept the JW modifier and reimburse accordingly. Others will not recognize it and they will not pay for wastage. To prevent the loss of funds or incorrect claims, billing teams need to have a payer specific reference that outlines each plan’s approach to drug wastage for RA infusion drugs.

 

RA Infusion Drugs Billing in Hospital Outpatient Settings

The facility at which you receive infusion services can also change the way it is billed. The claim format and revenue code system for HODs is different from the format and revenue codes for freestanding infusion centers and physician offices.

Claim Form and Revenue Codes

Hospital outpatient facilities submit claims on a UB 04 claim form, instead of a CMS 1500 claim. The RA infusion drug is reported with its J code and the administration service is reported under revenue code 636, which is for drug administration. Depending on the charge master structure of the facility, there may be additional revenue codes.

Professional vs Facility Billing

If the RA infusion is given in an outpatient department of a hospital, then two claims are generated. The facility charges for the room, nursing care and drug using its own NPI. When supervising or administering physician bills independently, the same CPT codes are used but under the professional fee schedule. Billing teams need to be aware of the exact nature of the facility side or professional side of the business to ensure that they do not invoice twice or miss charges.

Place of Service Code

Place of Service code 22 should be used for professional claims submitted in a hospital outpatient environment. Failure to use the appropriate place of service code will lead to reimbursement at the wrong rate or claims for RA infusion drugs will be denied in this scenario.

 

Payer Specific Guidelines for RA Infusion Drugs Claims

The payment terms for RA infusion drugs can be quite different and should be investigated on a plan-by-plan basis. The actual coverage and documentation guidelines that are applicable to the major categories of payers are listed below.

Medicare Guidelines

If a RA infusion drug is used in an outpatient clinical setting, it will be covered by Medicare Part B. Coverage is determined by Medicare Administrative Contractor’s Local Coverage Determinations. The drug must be FDA approved for RA and the claim must contain an ICD 10 diagnosis code that is related to the appropriate LCD. Medicare does need the NDC number on claims for separately payable drugs and the JW or JZ modifier must be added as appropriate for vial wastage.

Medicare Advantage Guidelines

There are Medicare Advantage plans that adhere to Medicare guidelines as a minimum requirement and may include extra conditions. Biologic RA infusion drugs are often subject to step therapy documentation before being approved by many Medicare Advantage plans. Authorisation periods last for 6 to 12 months and need to be renewed proactively. Some Medicare Advantage plans may specify that infusions be given at a preferred location or within their network of care.

Commercial Payer Guidelines

Each commercial insurer, including UnitedHealthcare, Aetna, Cigna and BlueCross BlueShield, has clinical coverage policies for RA biologics. Factors common across these payers include documentation of a confirmed diagnosis of moderate to severe RA supported by lab and clinical evidence. Documentation of an adequate trial and failure of methotrexate or other DMARDs; physician attestation. That the selected biologic is medically necessary; and site of care requirements, which may direct patients to lower cost infusion settings. Clinical policies are reviewed and updated every year, and shall be reviewed at the beginning of each calendar year.

Medicaid Guidelines

Medicaid will cover the cost of infusion drugs for RA in different states. Almost all state Medicaid programs mandate prior authorization, and also have their own preferred formulary. In some states, the biosimilar must be tried first before the approval of the branded biologic. Billing teams are required to verify the coverage status, authorization needs, and any supplemental documentation for any particular Medicaid plan in the state Medicaid portal.

 

How to Appeal Denied RA Infusion Drugs Claims Effectively

Most requests for RA infusion drugs are denied, but most of these can be successfully appealed with a targeted, well-prepared appeal. This is best done in a sequential manner and not just resubmitting the claim.

Step 1: Identify the Exact Denial Reason
Capture the Explanation of Benefits (eOB) or electronic remittance advice and find the relevant denial code and remark code. A generic appeal that does not refer to the specific cause of denial will hardly ever succeed. Common reasons for denial of RA infusion drugs are medical necessity, drug not covered, unit error, and no authorization on file.

Step 2: Request the Payer’s Clinical Criteria
If your claim was denied for medical necessity, ask the payer for a copy of its clinical coverage policy for the RA infusion drug. Your appeal should address each one of the criteria stated in that policy.

Step 3: Compile the Appeal Package
Create a complete appeal containing the original claim, denial notice, physician’s letter of medical necessity, complete clinical record to support the RA diagnosis, evidence of compliance with step therapy requirements, and any applicable clinical guidelines (from the American College of Rheumatology, for example).

Step 4: Address Authorization Denials Separately
If denial is related to prior authorization, provide documentation that a valid prior authorization was in place at the time of service, an authorization approval letter, and a history of the service date and when it was in the required period.

Step 5: Submit Within the Deadline

Typically, the payers give a 60 to 180 day appeal period after the denial date for the first level appeal. The failure to do so will result in the loss of your right to appeal completely. Make sure that all RA infusion drugs claims that are denied are tracked through your practice management system with all denial dates and appeal deadlines.

Step 6: Escalate to a Peer to Peer Review When Needed
If a first level appeal is not successful, ask the 1st level physician to appeal to another peer physician on the treating physician’s and the medical reviewer’s part. This is generally the best method for challenging medical necessity denials for RA infusion medications especially high cost biologics.

 

Best Practices for Accurate RA Infusion Drugs Billing

Accurate RA infusion drugs billing begins before the patient arrives for their infusion. Do not take authorization for granted. The clinical team should be informed of the documentation requirements, particularly with regards to start and end times, and preparation of the drugs. The charge entry will need someone who is familiar with both the J codes and CPT administration codes to review.

Claims should be submitted through a pre submission audit to ensure that units, modifiers, diagnosis codes and payer specific requirements are all correct. Under payment or missed billing of wastage is a natural thing to look for in a payment review process. These measures increase the time it takes to process claims for RA infusion drugs, but have the potential to decrease the overall amount of expensive rework and denials across the board.

 

How Infusion Billing Services Supports RA Claims

As an Infusion Billing Services provider, we are aware of the unique needs that are associated with billing for RA infusion drugs. We are dedicated to the infusion space, and stay up-to-date with all payer policies, J code changes and authorizations for your claims. From eligibility verification and tracking prior authorization to charge entry, claim submission and denial management, we have it all covered.

If there are denials for RA infusion drug claims, we will file appeals with the documentation and persistence required to get your revenue. With our help, our clients experience tangible results in their clean claim rates and shorter reimbursement cycles. For practices facing challenges with RA infusion drugs billing or looking to lower the denial rate and boost cash flow, contact Infusion Billing Services today. Here to ensure that your claims match the care you deliver.

 

Conclusion

Billing for RA infusion drugs is one of the most complex and challenging parts of infusion revenue cycle management. Each claim must include the appropriate J code, correct unit quantities, proper prior authorization and payor-specific documentation. The absence of any one of these will result in a payment delay or a denial. Fortunately, the majority of denials for infusion drugs for RA can be avoided through proper processes. 

If your team is familiar with the codes, follows the authorization process, and remains up-to-date on the payer’s guidelines, then your claims will go much better. The infusion drugs used to treat RA are costly services which should be reimbursed appropriately and on time. As with any collaborative effort, it makes a difference when a billing team specializes in infusion services. Your practice can trust infusion billing services to process and receive proper payment for every RA infusion drugs claim submitted.

 

Frequently Asked Questions

What are common RA infusion drugs billed today?

Infusion medications commonly used to treat RA include infliximab, abatacept, rituximab and tocilizumab. The HCPCS J code and payer billing requirements are different for each drug.

Which HCPCS code covers infliximab infusion claims?

The HCPCS code for infliximab is J1745. This is the code for 10mg per unit and should be the same as the unit that is administered.

Is prior authorization required for RA biologics?

Yes, all payers will need RA infusion drugs to be authorized first. Typically, documentation of step therapy and medical necessity letters are required for approval.

What CPT code starts an RA infusion claim?

CPT 96413 is for the initial hour of infusion. All hours thereafter are charged at CPT 96415 per additional hour.

What does the JW modifier mean in billing?

How does hospital outpatient RA billing differ?

UB 04 form is used with hospital outpatient billing revenue codes. In this case, facility and professional claims may be charged separately.

Can denied RA infusion drug claims be appealed?

Yes, there are many denials that can be appealed for RA infusion drugs. Clinical records, authorization proof, and step therapy documentation are examples of documents that assist in a strong appeal.

What causes most RA infusion billing denials?

Top causes are incorrect unit counts, missing authorization numbers and lack of documentation. Claim pre-submission review is the key to avoiding these common claims billing mistakes.

Do Medicaid plans cover RA biologic infusions?

The rules for Medicaid coverage differ from state to state and sometimes depend on the prior authorization process. In some states, there are biosimilar trials needed before approval of RA infusion drugs.

How does Infusion Billing Services help RA billing?

Infusion Billing Services handles authorization, coding, claim submission and claim denials. They have a team of infusion specialists who can work with practices to optimize the efficiency and speed of reimbursement and the clean claim rate.